HIV is an immunodeficiency disease with emergence of inadequate corresponding reconstruction therapies. Pyroptosis of CD4+T cell is mainly caused by immune activation and inflammation that cannot be reduced by successful antiretroviral therapy (ART) alone. Coinfections because of CD4+T cell reconstitution failure can occur. Anti-inflammatory treatment determines the success of immune reconstitution. In our experiment, only a few cytokines could recover to normal level following a 2-year antiretroviral treatment in early ART initiation, which is consistent with current findings about adjuvant HIV anti-inflammatory therapy. Early infection is often accompanied by a more severe inflammatory response. Innate immunity cytokines like granulocyte macrophage-colony stimulating factor, IFN-γ induced protein 10 kDa, and tumor necrosis factor-α exhibited the most elevated levels among all kinds of inflammatory cytokines. The correlation analysis showed at least eight cytokines contributing to the changes of CD4/CD8 ratio.
Get full access to this article
View all access options for this article.
References
1.
DoitshG, GallowayNL, GengX, et al.Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature, 2014; 505(7484):509–514.
2.
CorbeauP, ReynesJ. Immune reconstitution under antiretroviral therapy: The new challenge in HIV-1 infection. Blood, 2011; 117(21):5582–5590.
3.
CatalfamoM, Le SaoutC, LaneHC. The role of cytokines in the pathogenesis and treatment of HIV infection. Cytokine Growth Factor Rev, 2012; 23(4–5):207–214.
4.
PastorL, CasellasA, RupérezM, et al.Interferon-γ-inducible protein 10 (IP-10) as a screening tool to optimize human immunodeficiency virus RNA monitoring in resource-limited settings. Clin Infect Dis, 2017; 65(10):1670–1675.
5.
JohnstoneJ, ParsonsR, BotelhoF, et al.T-cell phenotypes predictive of frailty and mortality in elderly nursing home residents. J Am Geriatr Soc, 2017; 65(1):153–159.
6.
WikbyA, FergusonF, ForseyR, et al.An immune risk phenotype, cognitive impairment, and survival in very late life: Impact of allostatic load in Swedish octogenarian and nonagenarian humans. J Gerontol A Biol Sci Med Sci, 2005; 60(5):556–565.
7.
NdhlovuZM, KazerSW, NkosiT, et al.Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. Sci Transl Med, 2019; 11(493):eaau0528.
8.
GroupISS, LundgrenJD, BabikerAG, et al.Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med, 2015; 373(9):795–807.
9.
FattiG, GrimwoodA, NachegaJB, et al.Better virological outcomes among people living with human immunodeficiency virus (HIV) initiating early antiretroviral treatment (CD4 counts >/ = 500 cells/microL) in the HIV Prevention Trials Network 071 (PopART) trial in South Africa. Clin Infect Dis, 2020; 70(3):395–403.
10.
KazerSW, WalkerBD, ShalekAK. Evolution and diversity of immune responses during acute HIV infection. Immunity, 2020; 53(5):908–924.
11.
TranTA, GhosnJ, Avettand-FenoelV, et al.Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy. J Antimicrob Chemother, 2015; 70(9):2627–2631.
12.
TowersGJ, NoursadeghiM. Interactions between HIV-1 and the cell-autonomous innate immune system. Cell Host Microbe, 2014; 16(1):10–18.
13.
ZhouF, LiuX, ZuoD, et al.HIV-1 Nef-induced lncRNA AK006025 regulates CXCL9/10/11 cluster gene expression in astrocytes through interaction with CBP/P300. J Neuroinflammation, 2018; 15(1):303.
14.
ThormanJ, BjörkmanP, MarroneG, et al.Interferon-γ-inducible protein 10 (IP-10) kinetics after antiretroviral treatment initiation in ethiopian adults with HIV. Microbiol Spectr, 2021; 9(3):e0181021.
15.
RamirezLA, ArangoTA, ThompsonE, et al.High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART. J Leukoc Biol, 2014; 96(6):1055–1063.
16.
SeddikiN, FrenchM. COVID-19 and HIV-associated immune reconstitution inflammatory syndrome: Emergence of pathogen-specific immune responses adding fuel to the fire. Front Immunol, 2021; 12:649567.
17.
AlejosB, Suárez-GarcíaI, RavaM, et al.Effectiveness and safety of first-line antiretroviral regimens in clinical practice: A multicentre cohort study. J Antimicrob Chemother, 2020; 75(10):3004–3014.
18.
HeX, AidM, VenturaJD, et al.Rapid loss of CD4 T cells by pyroptosis during acute SIV infection in rhesus macaques. J Virol, 2022; 96(17):e0080822.
19.
LuW, DemersAJ, MaF, et al.Next-generation mRNA sequencing reveals pyroptosis-induced CD4+ T cell death in early simian immunodeficiency virus-infected lymphoid tissues. J Virol, 2016; 90(2):1080–1087.
20.
Du BruynE, FukutaniKF, RockwoodN, et al.Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: A prospective cohort study and immunological network analysis. Lancet Microbe, 2021; 2(8):e375–e385.
21.
HuntPW. Very early ART and persistent inflammation in treated HIV. Clin Infect Dis, 2017; 64(2):132–133.
22.
MilesSA, LeeK, HutlinL, et al.Potential use of human stem cell factor as adjunctive therapy for human immunodeficiency virus-related cytopenias. Blood, 1991; 78(12):3200–3208.
23.
IppH, ZemlinAE, ErasmusRT, et al.Role of inflammation in HIV-1 disease progression and prognosis. Crit Rev Clin Lab Sci, 2014; 51(2):98–111.
24.
AngelidouK, HuntPW, LandayAL, et al.Changes in inflammation but not in T-cell activation precede non-AIDS-defining events in a case-control study of patients on long-term antiretroviral therapy. J Infect Dis, 2018; 218(2):239–248.
25.
SnellLM, XuW, Abd-RabboD, et al.Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection. Nat Immunol, 2021; 22(12):1524–1537.
26.
MbheleN, ChimukangaraB, GordonM. HIV-1 integrase strand transfer inhibitors: A review of current drugs, recent advances and drug resistance. Int J Antimicrob Agents, 2021; 57(5):106343.
27.
HoangNT, NguyenNTT, NguyenQN, et al.Survival outcomes of Vietnamese people with HIV after initiating antiretroviral treatment: Role of clinic-related factors. AIDS Behav, 2021; 25(5):1626–1635.
28.
HopeTJ. Inflammation weakens HIV prevention. Nat Med, 2018; 24(4):384–385.
29.
ChammartinF, LodiS, LoganR, et al.Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study. Ann Intern Med, 2021; 174(6):768–776.
30.
Muñoz-AriasI, DoitshG, YangZ, et al.Blood-derived CD4 T cells naturally resist pyroptosis during abortive HIV-1 infection. Cell Host Microbe, 2015; 18(4):463–470.
31.
FinziD, HermankovaM, PiersonT, et al.Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science, 1997; 278(5341):1295–1300.
32.
CaoD, KhanalS, WangL, et al.A matter of life or death: Productively infected and bystander CD4 T cells in early HIV infection. Front Immunol, 2020; 11:626431.
33.
FertA, Raymond MarchandL, Wiche SalinasTR, et al.Targeting Th17 cells in HIV-1 remission/cure interventions. Trends Immunol, 2022; 43(7):580–594.
34.
BoardNL, MoskovljevicM, WuF, et al.Engaging innate immunity in HIV-1 cure strategies. Nat Rev Immunol, 2022; 22(8):499–512.
35.
KruizeZ, KootstraNA. The role of macrophages in HIV-1 persistence and pathogenesis. Front Microbiol, 2019; 10:2828.
36.
ThornhillJ, InshawJ, OomeerS, et al.Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection. J Int AIDS Soc, 2014; 17(4Suppl 3):19480.
37.
SandlerNG, SeretiI. Can early therapy reduce inflammation?. Curr Opin HIV AIDS, 2014; 9(1):72–79.
38.
HuntPW, LeeSA, SiednerMJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis, 2016; 214(Suppl 2):S44–50.
39.
RipaM, PogliaghiM, ChiappettaS, et al.Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial. Clin Microbiol Infect, 2015; 21(9):876.e871–e874.
40.
BrenchleyJM, PriceDA, SchackerTW, et al.Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006; 12(12):1365–1371.
41.
StaceyAR, NorrisPJ, QinL, et al.Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol, 2009; 83(8):3719–3733.
42.
AppayV, SauceD. Immune activation and inflammation in HIV-1 infection: Causes and consequences. J Pathol, 2008; 214(2):231–241.
43.
KrebsSJ, AnanworanichJ. Immune activation during acute HIV infection and the impact of early antiretroviral therapy. Curr Opin HIV AIDS, 2016; 11(2):163–172.
44.
TarrPE, CalmyA. Anti-inflammatory therapy in well controlled HIV infection. Lancet HIV, 2018; 5(10):e538–e539.
45.
LvT, CaoW, LiT. HIV-related immune activation and inflammation: Current understanding and strategies. J Immunol Res, 2021; 2021:7316456.
46.
ZhangY, JiangT, LiA, et al.Adjunct therapy for CD4(+) T-cell recovery, inflammation and immune activation in people living with HIV: A systematic review and meta-analysis. Front Immunol, 2021; 12:632119.
47.
HuQ, XuY, XiangY, et al.Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study. Int J Biol Sci, 2021; 17(8):2124–2134.
48.
RiveraA, SiracusaMC, YapGS, et al.Innate cell communication kick-starts pathogen-specific immunity. Nat Immunol, 2016; 17(4):356–363.
49.
MulderWJM, OchandoJ, JoostenLAB, et al.Therapeutic targeting of trained immunity. Nat Rev Drug Discov, 2019; 18(7):553–566.
50.
ShiY, SuJ, ChenR, et al.The role of innate immunity in natural elite controllers of HIV-1 infection. Front Immunol, 2022; 13:780922.
51.
HartanaCA, YuXG. Immunological effector mechanisms in HIV-1 elite controllers. Curr Opin HIV AIDS, 2021; 16(5):243–248.
52.
DoitshG, GreeneWC. Dissecting how CD4 T cells are lost during HIV infection. Cell Host Microbe, 2016; 19(3):280–291.
53.
ZicariS, SessaL, CotugnoN, et al.Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses, 2019; 11(3):200.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
